From the June 2025 issue of DOTmed Equipment Classifieds magazine
Johann Fernando Ph.D., Executive Vice President,
Spectrum Dynamics Medical
In the rapidly evolving landscape of nuclear medicine, theranostics—the fusion of therapy and diagnostics—is revolutionizing the way we treat complex diseases like cancer. At the forefront of this transformation stands the
VERITON-CT, a next-generation SPECT/CT system developed by
Spectrum Dynamics Medical. Engineered with advanced digital technology and a patient-centered design, VERITON-CT offers a quantum leap in performance, accuracy, and efficiency. It is not just a diagnostic tool—it is a powerful ally in the theranostic journey from diagnosis to treatment response.
Theranostics: Bridging Diagnostics and Targeted Therapy
Theranostics has emerged as a game-changer in nuclear medicine, particularly in the treatment of neuroendocrine tumors (NETs) and prostate cancer. By using the same molecular target for both imaging and treatment—such as Lu-177-labeled compounds for imaging and therapy—clinicians can deliver highly personalized, targeted care. This approach requires exceptional imaging precision, reliable quantification, and the ability to track disease progression and therapeutic response with confidence.
This is where the VERITON-CT from Spectrum Dynamics Medical stands apart.
Digital SPECT/CT Reimagined for Theranostics
Traditional SPECT imaging has often lagged behind PET in terms of resolution, sensitivity, and quantitative capabilities. VERITON-CT changes the narrative. Designed from the ground up as
a digital SPECT/CT system, VERITON-CT leverages
360-degree CZT detector technology—a breakthrough that delivers unprecedented image quality and speed.
With 12 digital detectors rotating around the patient in a full ring geometry, the system provides
uniform spatial resolution, high sensitivity, and low noise—essential features for accurately detecting small lesions, monitoring radiotracer uptake, and guiding therapy. This makes it ideally suited for theranostic protocols involving Lu-177, I-131, and other therapeutic isotopes.
Quantification That Drives Precision
Quantitative imaging is central to theranostics. Being able to measure the actual uptake of therapeutic agents allows clinicians to personalize dosimetry, optimize treatment plans, and improve outcomes. VERITON-CT incorporates
absolute quantification capabilities with
attenuation correction, scatter correction, and
calibration protocols that rival PET/CT systems in performance.
This means that nuclear medicine departments can now
reliably measure radiotracer distribution in organs and tumors, enabling accurate dose estimation for therapies like
Lu-177 DOTATATE or Lu-177 PSMA. Such quantification enhances not just treatment efficacy, but also safety—minimizing exposure to healthy tissue and reducing the risk of toxicity.
Theranostics Workflow, Transformed
Time is critical in theranostic care pathways. The VERITON-CT is designed with
efficiency and patient comfort in mind. Its open, non-claustrophobic gantry design and quiet operation reduce patient anxiety, improving compliance and scan success rates. Its high sensitivity allows for
shorter scan times and lower radiotracer doses, making it an ideal solution for vulnerable or high-risk patients.
The intuitive user interface and automation features streamline workflow, allowing technologists to focus on patient care rather than cumbersome imaging protocols. Whether used in outpatient therapy centers or high-volume academic institutions, VERITON-CT integrates seamlessly into existing theranostic programs while elevating their performance.
Real-World Impact
Institutions across the globe are already realizing the benefits of VERITON-CT in their theranostic practices. For example, leading European centers have reported
significantly improved lesion detectability, especially in cases of recurrent or metastatic prostate cancer following Lu-177 PSMA therapy. Others have noted that VERITON-CT’s enhanced image quality and quantification have
expanded eligibility for radionuclide therapy, opening doors for more patients to benefit from personalized care.
In research settings, VERITON-CT is accelerating the development of new theranostic agents and protocols. Its precision and repeatability provide a reliable platform for clinical trials, helping translate innovative science into everyday practice.
Future-Ready Imaging
Theranostics is still in its early stages, with exciting new radiopharmaceuticals on the horizon. The VERITON-CT is
future-ready—designed to evolve with the field. Its digital architecture and scalable software allow for ongoing updates and enhancements, ensuring that institutions remain at the cutting edge of molecular imaging and therapy.
Conclusion
As healthcare shifts toward precision medicine, theranostics represents one of the most promising frontiers in oncology and beyond. The VERITON-CT by Spectrum Dynamics is not merely keeping pace with this shift—it is helping to drive it. By combining
cutting-edge digital imaging, quantitative accuracy, and
workflow optimization, VERITON-CT empowers clinicians to deliver more effective, personalized treatments with confidence.
For nuclear medicine teams seeking to elevate their theranostic capabilities, the VERITON-CT is more than a system—it is a strategic investment in the future of patient care.
To learn more about how VERITON-CT can transform your theranostic practice, visit spectrum-dynamics.com.
